All In Biotech

Investigational drug · Phase 3

HLX17

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Non-Squamous Non-Small Cell Lung Cancer.

Phase 3

Last checked: Nov 19, 2026Latest source record: Feb 26, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

2

Any phase or sponsor naming "HLX17"

First trial start

2025

Apr 27, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "HLX17", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Non-Squamous Non-Small Cell Lung Cancer

Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "HLX17" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Non-Squamous Non-Small Cell Lung Cancer

  • IvonescimabAK112, SMT112Phase 349 trials

    Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors

  • AdebrelimabSHR-8068, HRS -4642Phase 341 trials

    Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors

  • BL-M07D1Phase 317 trials

    Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors

  • Telisotuzumab AdizutecanABBV-400Phase 316 trials

    AbbVie · c-MET, Non-Squamous Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer

  • CamrelizumabSHR-1210, CAMPhase 39 trials

    Jiangsu HengRui Medicine Co., Ltd. · HCC, Non-squamous Non-small Cell Lung Cancer, Hepatocellular Carcinoma

  • AumolertinibSHR-A2009, HS-10296Phase 37 trials

    Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Non-Squamous Non-Small Cell Lung Cancer, Advanced Solid Tumors

  • EU-sourced KeytrudaPhase 32 trials

    Shanghai Henlius Biotech · Non-Squamous Non-Small Cell Lung Cancer, Non Squamous Non Small Cell Lung Cancer

  • US-sourced KeytrudaPhase 32 trials

    Shanghai Henlius Biotech · Non-Squamous Non-Small Cell Lung Cancer, Non Squamous Non Small Cell Lung Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.